The ability to target and modify specific genomic sequences holds promise for treating a myriad of genetic disorders, from monogenic diseases to complex, multifactorial conditions. In practice, however, CRISPR-based therapeutics must enter the desired cells without eliciting an unwanted immune response, so a delivery system is required. Thus, despite its transformative potential, the therapeutic application of CRISPR faces significant challenges, particularly in the realm of delivery systems. Effective and safe delivery of CRISPR components -such as the Cas9 nuclease and sgRNA) -to target cells and tissues, is paramount for achieving desired therapeutic outcomes while minimizing off-target effects and immune responses. The choice of delivery method can significantly influence the efficiency, specificity, and safety of CRISPRmediated gene editing.